Solicitation of Nominations for Appointment to the Communications and Public Engagement Workgroup of the Advisory Committee to the Director, CDC; Notice of Extension, 22727-22728 [2024-06893]
Download as PDF
<![CDATA[
Federal Register / Vol. 89, No. 64 / Tuesday, April 2, 2024 / Notices
of publication of this notice to
www.reginfo.gov/public/do/PRAMain.
Find this particular information
collection by selecting ‘‘Currently under
Review—Open for Public Comments’’ or
by using the search function.
FOR FURTHER INFORMATION CONTACT:
Elizabeth Martin, Program Manager,
267–455–8556 at
arp.national.evaluation@gsa.gov.
SUPPLEMENTARY INFORMATION:
khammond on DSKJM1Z7X2PROD with NOTICES
A. Purpose
The goal of this study is to look
systematically across the selected subset
of ARP programs, to provide an
integrated account of whether, how, and
to what extent their implementation
served to achieve their intended
outcomes, particularly with respect to
advancing equity. More specifically, the
study aims to learn how lessons from
examination of ARP programs and
interventions with shared outcomes,
common approaches, or overlapping
recipient communities may inform
equitable program design and delivery
across the Federal Government. The
study aims to address these overarching
evaluation questions:
• To what extent did ARP
investments and policy interventions
advance equitable outcomes for those
they were designed to serve?
• What strategies contributed to the
successes, and where are different
strategies needed?
• Where multiple ARP programs aim
to reach similar outcomes, especially
among a shared population:
Æ To what extent is there
coordination across programs in their
administration, customer experience
strategies, or performance or outcome
measurement practices?
Æ To what extent are there collective
impacts that could be attributed to more
than one program? What kinds of
impacts, if any, are observed?
Æ What kinds of secondary effects are
observed that may not be captured in
targeted outcome measures?
The list of 32 programs covered in the
May 2022 White House report
‘‘Advancing Equity through the
American Rescue Plan’’ provided the
scope of programs included in the
National Evaluation. A partnership
between the Office of Management and
Budget Evidence Team and GSA’s
Office of Evaluation Sciences, this study
is also guided by leadership from the
White House ARP Implementation
Team, who participate on the Steering
Committee, as well as a team of agency
experts across the Federal Government.
To build evidence in support of the
study goals, this project includes a
VerDate Sep<11>2014
17:06 Apr 01, 2024
Jkt 262001
series of up to five in-depth, crosscutting evaluations of selected ARP
programs or recipient communities of
multiple ARP program investments with
shared outcomes, common approaches,
or overlapping recipient groups. These
evaluations will be selected based on
program, population, place, community,
or a combination of these factors. A
mixed-methods approach is anticipated
in order to ensure that appropriate
attention is paid to context and that data
collection and analysis methods reflect
the complexity of program
implementation and address the specific
evaluation questions identified through
the ongoing planning and consultation
process.
The ARP National Evaluation will use
a multiple-phased approach for this
proposed information collection
activity. In Phase 1 (current request) the
research team seeks approval to carry
out consultations with the relevant state
and local agencies, community-based
organizations, and program participants,
including the formal recruitment
process to establish community
advisory boards for each of the planned
in-depth evaluations.
Under subsequent phases of the
request, the project will update the
information collection request for the
instruments tailored to each in-depth
evaluation, to reflect the specific
evaluation design, information
collection methods and instruments,
and associated burden. The proposed
information collection activities cover
mixed-method approaches to implement
primarily outcome and process
evaluations. Data collection activities
for these studies may include: (1)
interviews with program administrators
and staff; (2) focus groups, (3) short
surveys of program participants and/or
eligible non-participants, and (4) data
requests.
Respondents: State and local program
administrators, program staff,
community-based program partners, and
individuals who participate or are
eligible to participate in the relevant
ARP programs.
B. Annual Burden Estimates
Currently, three cross-cutting in-depth
evaluations are anticipated. The burden
estimates below reflect the expectations
for information collection and related
activities associated with the conduct of
those three studies, in addition to the
anticipated burden for this initial,
formative phase of the overall study.
During Phase 1, we estimate the
following: consultations with
approximately 95 state and/or local
program administrators or
representatives from community-based
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
22727
organizations, recruitment of up to 9
participants for each of up to seven
Community Advisory Groups
established across the three studies, and
the initiation of the group meetings.
The anticipated information
collections to be undertaken in Phase 2
are expected to vary in their approaches
to data collection and sample size. The
subsequent information collection
requests will describe the specific study
design and associated burden for each
evaluation. The estimates below include
our current expectations for the burden
associated with these evaluations.
Total Respondents: 1,241.
Total Annual Responses: 15.
Average Burden Hours per Response:
1.9.
Total Burden Hours: 3,034.5.
C. Public Comments
A 60-day notice published in the
Federal Register at 88 FR 85621 on
December 8, 2023. Two comments were
received, but neither provided
substantive comments relevant to this
specific information collection request.
Obtaining Copies: Requesters may
obtain a copy of the information
collection documents from the GSA
Regulatory Secretariat Division, by
calling 202–501–4755 or emailing
GSARegSec@gsa.gov. Please cite OMB
Control No. 3090–XXXX, Data
Collection for a National Evaluation of
the American Rescue Plan.
Lois Mandell,
Director, Regulatory Secretariat Division,
General Services Administration.
[FR Doc. 2024–06913 Filed 4–1–24; 8:45 am]
BILLING CODE 6820–TZ–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Solicitation of Nominations for
Appointment to the Communications
and Public Engagement Workgroup of
the Advisory Committee to the
Director, CDC; Notice of Extension
Centers for Disease Control and
Prevention, Department of Health and
Human Services (HHS).
ACTION: Notice.
AGENCY:
In accordance with the
Federal Advisory Committee Act, the
Centers for Disease Control and
Prevention (CDC), within the
Department of Health and Human
Services (HHS), is seeking nominations
for membership on the Communications
and Public Engagement Workgroup
SUMMARY:
E:\FR\FM\02APN1.SGM
02APN1
22728
Federal Register / Vol. 89, No. 64 / Tuesday, April 2, 2024 / Notices
khammond on DSKJM1Z7X2PROD with NOTICES
(CPEW) of the Advisory Committee to
the Director, CDC. The CPEW consists of
approximately 15 members who are
experts in fields associated with
communications, including public
relations, health communication, risk
communication, communication
research, and marketing; community
and partner engagement; public health
science and practice, including
implementation; and behavioral
science/behavior change campaigns.
DATES: The deadline for submission of
nominations for membership on the
CPEW published March 4, 2024, at 89
FR 15578, is extended. Nominations for
membership on the CPEW must be
received no later than April 26, 2024.
Late nominations will not be considered
for membership.
ADDRESSES: All nominations (cover
letters, reference letters, and curriculum
vitae/resumes) should be emailed to
ACDirector@cdc.gov with the subject
line: ‘‘Nomination for CDC ACD
Communications and Public
Engagement Workgroup.’’
FOR FURTHER INFORMATION CONTACT: Kate
Galatas, M.P.H., Senior
Communications Specialist, Office of
Communications, Centers for Disease
Control and Prevention, 1600 Clifton
Road NE, Mailstop H21–11, Atlanta, GA
30329–4027. Telephone: (404) 639–
2064; Email: ACDirector@cdc.gov.
The Director, Office of Strategic
Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
SUPPLEMENTARY INFORMATION: The
deadline for nominations for
appointment to the Communications
and Public Engagement Workgroup
(CPEW) of the Advisory Committee to
the Director, Centers for Disease Control
and Prevention has been extended from
March 28, 2024 to April 26, 2024. The
original solicitation of nominations
notice was published in the Federal
VerDate Sep<11>2014
17:06 Apr 01, 2024
Jkt 262001
Register on March 4, 2024, Volume 89,
Number 43, pages 15578–15579.
Kalwant Smagh,
Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2024–06893 Filed 4–1–24; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2022–D–1173]
Electronic Submission of Expedited
Safety Reports From Investigational
New Drug-Exempt Bioavailability/
Bioequivalence Studies; Guidance for
Industry; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of availability.
The Food and Drug
Administration (FDA or Agency) is
announcing the availability of a final
guidance for industry entitled
‘‘Electronic Submission of Expedited
Safety Reports From IND-Exempt BA/BE
Studies.’’ This guidance provides
instructions for the electronic
submission of expedited individual case
safety reports (ICSRs) from
investigational new drug (IND)-exempt
bioavailability (BA)/bioequivalence (BE)
studies to the FDA Adverse Event
Reporting System (FAERS). This
guidance finalizes the draft guidance
entitled ‘‘Electronic Submission of
Expedited Safety Reports From INDExempt BA/BE Studies’’ issued on
August 3, 2022.
DATES: The announcement of the
guidance is published in the Federal
Register on April 2, 2024.
ADDRESSES: You may submit either
electronic or written comments on
Agency guidances at any time as
follows:
SUMMARY:
Electronic Submissions
Submit electronic comments in the
following way:
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand Delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2022–D–1173 for ‘‘Electronic
Submission of Expedited Safety Reports
from IND-Exempt BA/BE Studies.’’
Received comments will be placed in
the docket and, except for those
submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday, 240–402–7500.
E:\FR\FM\02APN1.SGM
02APN1
]]>Agencies
[Federal Register Volume 89, Number 64 (Tuesday, April 2, 2024)]
[Notices]
[Pages 22727-22728]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-06893]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Solicitation of Nominations for Appointment to the Communications
and Public Engagement Workgroup of the Advisory Committee to the
Director, CDC; Notice of Extension
AGENCY: Centers for Disease Control and Prevention, Department of
Health and Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Federal Advisory Committee Act, the
Centers for Disease Control and Prevention (CDC), within the Department
of Health and Human Services (HHS), is seeking nominations for
membership on the Communications and Public Engagement Workgroup
[[Page 22728]]
(CPEW) of the Advisory Committee to the Director, CDC. The CPEW
consists of approximately 15 members who are experts in fields
associated with communications, including public relations, health
communication, risk communication, communication research, and
marketing; community and partner engagement; public health science and
practice, including implementation; and behavioral science/behavior
change campaigns.
DATES: The deadline for submission of nominations for membership on the
CPEW published March 4, 2024, at 89 FR 15578, is extended. Nominations
for membership on the CPEW must be received no later than April 26,
2024. Late nominations will not be considered for membership.
ADDRESSES: All nominations (cover letters, reference letters, and
curriculum vitae/resumes) should be emailed to [email protected] with
the subject line: ``Nomination for CDC ACD Communications and Public
Engagement Workgroup.''
FOR FURTHER INFORMATION CONTACT: Kate Galatas, M.P.H., Senior
Communications Specialist, Office of Communications, Centers for
Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H21-11,
Atlanta, GA 30329-4027. Telephone: (404) 639-2064; Email:
[email protected].
The Director, Office of Strategic Business Initiatives, Office of
the Chief Operating Officer, Centers for Disease Control and
Prevention, has been delegated the authority to sign Federal Register
notices pertaining to announcements of meetings and other committee
management activities, for both the Centers for Disease Control and
Prevention and the Agency for Toxic Substances and Disease Registry.
SUPPLEMENTARY INFORMATION: The deadline for nominations for appointment
to the Communications and Public Engagement Workgroup (CPEW) of the
Advisory Committee to the Director, Centers for Disease Control and
Prevention has been extended from March 28, 2024 to April 26, 2024. The
original solicitation of nominations notice was published in the
Federal Register on March 4, 2024, Volume 89, Number 43, pages 15578-
15579.
Kalwant Smagh,
Director, Office of Strategic Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2024-06893 Filed 4-1-24; 8:45 am]
BILLING CODE 4163-18-P
